Total votes: 11

2008-2009 financial year saw:

Loss of approx.: $1.95 million

Income: approx. $0.8 million (predominnatly grants)

Cash: $1.6 million at March 30th 2010.

Anteo Diagnostics Limited Formerly known as BioLayer Corporation Limited. The Group's principal activities are developing and commercialising specialised surfaces used in the development and manufacture of immunoassays.

The company attenpts to convert novel biomarkers into clinical tools that predict, diagnose and track diseases and monitor therapeutic effects. In the process, data is aimed to be generated for the rapidly evolving and human healthcare information business.

Parnterships include:

Prince of Wales Medical Research Institute (POWMRI) - Parkinson's Disease

Manawatu Diagnostics Ltd. (ovarian monitoring)

Bangs Laboratories, Inc. based in the USA

The Board of Anteo announced that it has agreed on the terms of a “Non-Exclusive Supply Agreement” with Merck Chimie SAS which was announced in July 2010  -no revenue estimates provided at the time of eth announcement.

Other Efforts have included:

Work with Alzyhme to develop a novel Alzheimer's blood test.